array:23 ["pii" => "S0300289623003666" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.10.011" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3429" "copyright" => "SEPAR" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Arch Bronconeumol. 2024;60:65-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0300289623003800" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.11.012" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3441" "copyright" => "SEPAR" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Arch Bronconeumol. 2024;60:67-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "Letter to the Director" "titulo" => "Reply to Figueroa-Gonçalves and de Miguel-Díez" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "68" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marc Miravitlles, Konstantinos Kostikas, Nikoletta Bizymi, Nikolaos Tzanakis" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Marc" "apellidos" => "Miravitlles" ] 1 => array:2 [ "nombre" => "Konstantinos" "apellidos" => "Kostikas" ] 2 => array:2 [ "nombre" => "Nikoletta" "apellidos" => "Bizymi" ] 3 => array:2 [ "nombre" => "Nikolaos" "apellidos" => "Tzanakis" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003800?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003800/v3_202406051404/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0300289623003654" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.11.003" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3428" "copyright" => "The Author(s)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Bronconeumol. 2024;60:62-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Scientific Letter" "titulo" => "Persistent Pulmonary Fibrotic Sequelae in Patients With Telomere Shortening One Year After Severe COVID-19" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "62" "paginaFinal" => "64" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 902 "Ancho" => 2341 "Tamanyo" => 120516 ] ] "descripcion" => array:1 [ "en" => "Evolution of telomere shortening over one year after severe COVID-19. (A) Representation of relative telomere length (RTL) of patients admitted for bilateral COVID-19 pneumonia at admission and 1 year after discharge compared to controls. (B) RTL changes in patients without fibrosis. (C) RTL changes in patients with fibrosis." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alba Mulet, Pilar González-Cabo, Federico V. Pallardó, Jaime Signes-Costa" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Alba" "apellidos" => "Mulet" ] 1 => array:2 [ "nombre" => "Pilar" "apellidos" => "González-Cabo" ] 2 => array:2 [ "nombre" => "Federico V." "apellidos" => "Pallardó" ] 3 => array:2 [ "nombre" => "Jaime" "apellidos" => "Signes-Costa" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003654?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003654/v3_202406051404/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Letter to the Director" "titulo" => "Initial Treatment in COPD Patients. Do We Take into Account the Severity of the Exacerbation?" "tieneTextoCompleto" => true "saludo" => "To the Director," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "65" "paginaFinal" => "66" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Juan Marco Figueira-Gonçalves, Javier de Miguel-Díez" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Juan Marco" "apellidos" => "Figueira-Gonçalves" "email" => array:1 [ 0 => "juanmarcofigueira@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Javier" "apellidos" => "de Miguel-Díez" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Pneumology and Thoracic Surgery Service, Unit for Patients with Highly Complex COPD, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "University Institute of Tropical Disease and Public Health of the Canary Islands, University of La Laguna, Santa Cruz de Tenerife, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Respiratory Department, Gregorio Marañón General University Hospital, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Faculty of Medicine, Complutense University of Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1537 "Ancho" => 2508 "Tamanyo" => 184741 ] ] "descripcion" => array:1 [ "en" => "Proposal for initial pharmacological treatment. Low risk: Patients who present mild or moderate airflow obstruction, low degree of dyspnea (mMRC of 0–1) and ≤1 exacerbation that has not required admission (all criteria must be met). High risk: Patients who present severe or very severe airflow obstruction, a high degree of dyspnea (mMRC≥2) and/or at least ≥2 moderate exacerbations in the previous year or at least 1 that required hospital admission (at least 1 criterion must be met). Abbreviations: LAMA: long-acting muscarinic antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; Eo: eosinophils." ] ] ] "textoCompleto" => "We have read with special interest the article by Miravitlles et al. in which a simple algorithm is proposed for the initial treatment of chronic obstructive pulmonary disease (COPD) based on the GOLD ABE proposal.<a class="elsevierStyleCrossRef" href="#bib0030">1</a> Following the GOLD 2023 scheme, the indication for triple therapy with LAMA-LABA-ICS (LAMA: long-acting muscarinic antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid) as initial therapy in the exacerbator patient (patients with ≥2 moderate exacerbations or ≥1 exacerbation leading to hospitalization) will depend on the degree of peripheral eosinophilia (greater than 300cells per μL) without taking into account the exacerbation severity. Both scenarios (COPD exacerbation requiring hospital admission and frequent exacerbations with outpatient management) have shown to have short, medium and long-term clinical implications including accelerated loss of lung function, poor long-term survival, high impact on health status, development of cardiovascular events and increase in healthcare costs. However, these aspects are especially critical in those exacerbations that require hospital management.According to data extracted from the AUDIPOC study, up to 35% of COPD patients admitted for an exacerbation are readmitted after 90 days,<a class="elsevierStyleCrossRef" href="#bib0035">2</a> which reflects the difficulty in controlling these events and the need to optimize treatment upon discharge. On the other hand, start maintenance inhaled therapy for the first time after a severe exacerbation is not an uncommon situation. In a study carried out by Balcells et al.<a class="elsevierStyleCrossRef" href="#bib0040">3</a> in which characteristics of patients with COPD who were admitted for the first time due to an exacerbation were analyzed, it was described that around 40% of them did not receive prior inhaled treatment. In this context, the treatment prescribed at discharge would be considered as “initial therapy” according to the GOLD 2023 guideline. To date, multiple studies support the role of inhaled corticosteroids in preventing exacerbations. A post hoc analysis of the IMPACT study demonstrates that the initiation of LAMA-LABA-ICS triple therapy after a severe COPD exacerbation provides a greater benefit in terms of the development of future exacerbations than LAMA-LABA therapy in those patients with a level of eosinophils in peripheral blood>100cells per μL.<a class="elsevierStyleCrossRef" href="#bib0045">4</a> Added to these results are those presented in the PRIMUS study, which describes that early initiation of triple therapy after a severe exacerbation is associated with lower morbidity and economic burden. Based on all this, the recent publication of the document “Referral criteria in COPD. Continuity of care”,<a class="elsevierStyleCrossRef" href="#bib0050">5</a> proposes anticipating the prescription of LAMA-LABA-ICS as initial therapy in subjects with a severe exacerbation of COPD who present an eosinophil count in peripheral blood greater than 100cells per μL (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).<a class="elsevierStyleCrossRef" href="#bib0050">5</a> This approach is intended to maximize treatment and thus avoid future adverse events.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Authors’ contributionAll authors have made substantial contributions to the intellectual content and manuscript design and drafting.Authors’ approvalAll authors gave their approval to the final version of the manuscript and declare to have met the requirements for authorship.FundingAll authors declare that there is no funding in this manuscript.Conflicts of interestJavier de Miguel-Díez has received honoraria and funding from Laboratories AstraZeneca, Bial, Boehringer, Chiesi, Esteve, FAES, Ferrer, Gebro Pharma, GlaxoSmithKline, Janssen, Menarini, MundiPharma, Novartis, Roche, Rovi, Teva y Pfizer. Juan Marco Figueira-Gonçalves has received honoraria for speaking engagements and funding for conference attendance from Laboratories Esteve, MundiPharma, AstraZeneca, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GlaxoSmithKline, Chiesi, Novartis, and Gebro Pharma." "textoCompletoSecciones" => array:1 [ "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Authors’ contribution" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Authors’ approval" ] 2 => array:2 [ "identificador" => "sec0020" "titulo" => "Funding" ] 3 => array:2 [ "identificador" => "sec0015" "titulo" => "Conflicts of interest" ] 4 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1537 "Ancho" => 2508 "Tamanyo" => 184741 ] ] "descripcion" => array:1 [ "en" => "Proposal for initial pharmacological treatment. Low risk: Patients who present mild or moderate airflow obstruction, low degree of dyspnea (mMRC of 0–1) and ≤1 exacerbation that has not required admission (all criteria must be met). High risk: Patients who present severe or very severe airflow obstruction, a high degree of dyspnea (mMRC≥2) and/or at least ≥2 moderate exacerbations in the previous year or at least 1 that required hospital admission (at least 1 criterion must be met). Abbreviations: LAMA: long-acting muscarinic antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; Eo: eosinophils." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel figure and algorithm for the gold ABE classification" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Miravitlles" 1 => "K. Kostikas" 2 => "N. Bizymi" 3 => "N. Tzanakis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2023" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD audit" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Hartl" 1 => "J.L. Lopez-Campos" 2 => "F. Pozo-Rodriguez" 3 => "A. Castro-Acosta" 4 => "M. Studnicka" 5 => "B. Kaiser" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.01391-2014" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2016" "volumen" => "47" "paginaInicial" => "113" "paginaFinal" => "121" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26493806" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characteristics of patients admitted for the first time for COPD exacerbation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Balcells" 1 => "J.M. Antó" 2 => "J. Gea" 3 => "F.P. Gómez" 4 => "E. Rodríguez" 5 => "A. Marin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Respir Med" "fecha" => "2009" "volumen" => "103" "paginaInicial" => "1293" "paginaFinal" => "1302" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of exacerbation history on outcomes in the IMPACT trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.M.G. Halpin" 1 => "M.T. Dransfield" 2 => "M.K. Han" 3 => "C.E. Jones" 4 => "S. Kilbride" 5 => "P. Lange" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.01921-2019" "Revista" => array:5 [ "tituloSerie" => "Eur Respir J" "fecha" => "2020" "volumen" => "55" "paginaInicial" => "1901921" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32299860" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "SEMERGEN, SEPAR, semFYC, SEMG, SEFAC, GRAP. Criterios de derivación en EPOC. Continuidad asistencial. IMC 2023, Madrid. ISBN: 978-84-19457-41-7. Depósito legal: M-18163-2023." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003666/v3_202406051404/en/main.assets" "Apartado" => array:4 [ "identificador" => "94562" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Letters to the Director" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/03002896/0000006000000001/v3_202406051404/S0300289623003666/v3_202406051404/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003666?idApp=UINPBA00003Z"]

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is an international journal that publishes original studies whose content is based upon results of research initiatives dealing with several aspects of respiratory medicine including epidemiology, respiratory physiology, pathophysiology of respiratory diseases, clinical management, thoracic surgery, pediatric lung diseases, respiratory critical care, respiratory allergy and basic research. Other types of articles such as editorials, reviews, and different types of letters are also published in the journal. Additionally, the journal expresses the voice of the following scientific societies: the Spanish Respiratory Society of Pneumology and Thoracic Surgery (SEPAR; https://www.separ.es/), the Latin American Thoracic Society (ALAT; https://alatorax.org/), and the Iberian American Association of Thoracic Surgery (AIACT; http://www.aiatorax.com/).

It is a monthly journal in which all manuscripts are sent to peer-review and handled by the editor or an associate editor from the team and the final decision is made on the basis of the comments from the expert reviewers and the editors. The journal is published solely in English. All the published data is composed of novel manuscripts not previously published in any other journal and not being in consideration for publication in any other journal..

The journal is indexed at Science Citation Index Expanded, Medline/Pubmed, Embase and SCOPUS. Access to any published article is possible through the journal's web page as well as from Pubmed, ScienceDirect, and other international databases. Furthermore, the journal is also present in X, Facebook and Linkedin. Manuscripts can be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

8.7

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.5

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.464

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.482

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Export reference

Download PDF

Purchase article

For the purchase of this article it is necessary to fill in the following form:

Name *

First surname *

Second surname

Email *

Address *

Number *

City *

Afganistan

Albania

Alemania

Andorra

Angola

Anguilla

Antartica

Antigua and barbuda

Antillas holandesas

Arabia saudita

Argelia

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgica

Belice

Benin

Bermudas/antillas britanicas

Bhutan

Bolivia

Bosnia y herzegowina

Botswana

Brasil

Brunei darussalam

Bulgaria

Burkina faso

Burundi

Cabo verde

Camboya

Camerun

Canada

Chad

Chile

China

Chipre

Colombia

Comoros

Corea

Costa rica

Cote d´ivoire

Croacia

Cuba

Dinamarca

Djibouti

Dominica

East timor

Ecuador

Egipto

El salvador

Emiratos arabes unidos

Eritrea

Escocia

Eslovaquia

Eslovenia

España

Estados federados de micronesia

Estados unidos

Estonia

Etiopia

Fiji

Filipinas

Finlandia

Francia

Gabon

Gambia

Georgia

Ghana

Gibraltar

Grecia

Grenada

Groenlandia

Guadalupe

Guam

Guatemala

Guayana britanica

Guinea

Guinea ecuatorial

Guinea francesa

Guinea-bissau

Haiti

Holanda

Honduras

Hong kong

Hungria

India

Indonesia

Irak

Iran

Irlanda

Isla bouvet

Isla cocos (keeling)

Isla cook

Isla mauricio

Isla navidad

Isla norfolk

Islandia

Islas caiman

Islas falkland (malvinas)

Islas faroe

Islas georgia del sur y sandwich

Islas heard and mc donald

Islas marshall

Islas northern mariana

Islas salomon

Islas svalbard and jan mayen

Islas turks and caicos

Islas united states minor outlyi

Islas virgenes (britanicas)

Islas virgenes (u.s.a.)

Islas wallis and futuna

Israel

Italia

Jamaica

Japon

Jordania

Kazakhstan

Kenia

Kiribati

Kuwait

Kyrgyzstan

Lesoto

Letonia

Libano

Liberia

Libia arab jamahiriya

Liechtenstein

Lituania

Luxemburgo

Macao

Macedonia

Madagascar

Malasia

Malawi

Maldives

Mali

Malta

Marruecos

Martinica

Mauritania

Mayotte

Mexico

Monaco

Mongolia

Monserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Nicaragua

Niger

Nigeria

Niue

Noruega

Nueva caledonia

Nueva zelanda

Oman

Pakistan

Palau

Panama

Papua new guinea

Paraguay

Peru

Pitcairn

Polinesia francesa

Polonia

Portugal

Posesiones gran bretaña

Posesiones u.s.a.

Puerto rico

Qatar

Reino unido

Republica checa

Republica de africa central

Republica de cabo verde

Republica de congo

Republica de corea

Republica de moldova

Republica democratica de laos

Republica democratica del congo

Republica dominicana

Reunion

Ruanda

Rumania

Rusia

Sahara occidental

Saint kitts and nevis

Samoa

Samoa americana

San marino

San tomas y principe

San vincent and the grenadines

Santa lucia

Senegal

Serbia

Seychelles

Sierra leona

Singapur

Siria

Somalia

Sri lanka

St. helena

St. pierre and miquelon

Sudafrica

Sudan

Suecia

Suiza

Surinam

Swaziland

Tailandia

Taiwan republica de china

Tajikistan

Tanzania

Territorio de indias britanicas

Togo

Tokelau

Tonga

Trinidad and tobago

Tunisia

Turkmenistan

Turquia

Tuvalu

Ucrania

Uganda

Uruguay

Uzbekistan

Vanuatu

Vaticano

Venezuela

Vietnam

Yemen

Yugoslavia

Zambia

Zimbawe

Lebanon

Paises bajos

A coruña

Alava

Albacete

Alicante

Almeria

Asturias

Avila

Badajoz

Balears

Barcelona

Bizkaia

Burgos

Caceres

Cadiz

Cantabria

Castellon

Ceuta

Ciudad real

Cordoba

Cuenca

Girona

Granada

Guadalajara

Guipuzcoa

Huelva

Huesca

Jaen

La rioja

Las palmas

Leon

Lleida

Lugo

Madrid

Malaga

Melilla

Murcia

Navarra

Ourense

Palencia

Pontevedra

Salamanca

Segovia

Sevilla

Soria

Tarragona

Tenerife

Teruel

Toledo

Valencia

Valladolid

Zamora

Zaragoza

-- Not applicable --

Código postal *

Phone *

NIF o número identificativo *

I accept to receive information about Elsevier's special products and promotions by email

I accept to receive information about products and special promotions from Elsevier partners by email

I have read and understand the Privacy Policy and Terms and conditions and agree to be bound by all of its terms.

* Required fields

In addition to temporary access to the article, it will be sent by email.

Customer Support

Phone

Calls from Spain

932 415 960

Calls from abroad

+34 932 415 960

Hours from 9 a.m. to 6 p.m. except the months of July and August, which will be from 9 am to 3 pm.

Publish in

Archivos de Bronconeumología

Free access articles

Effects of Posture on the Inspiratory and Expiratory...

10.1016/j.arbres.2024.09.011

Pulmonary Hamartoma With Rare Imaging...

10.1016/j.arbres.2024.09.015

Corrigendum to “Chronic respiratory diseases as a...

Arch Bronconeumol. 2024;60:539-40

Podcast

Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

Graphical abstract

Archivos de Bronconeumología is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Archivos de Bronconeumología follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Purchase article

Subscribe to our newsletter